Aktienanalyse zu Kyntra Bio Inc (KYNB)KYNBKyntra Bio Inc

Kyntra Bio, Inc., formerly FibroGen, Inc., is a biopharmaceutical company. The Company is focused on development of novel therapies in oncology and rare disease. The Company continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. It operates in the Healthcare sector.

Kyntra Bio Inc is not a good buy right now due to its extremely low RSI of 16.241, indicating oversold conditions, and a significant year-to-date decline of 61.02%. The company has reported a net income of $12 million in Q2 2026, but the overall financial performance remains concerning with a gross margin of -81.45% in Q2 2026. The main risk is the negative earnings per share estimate of -3.66 for the upcoming earnings report, which could further impact investor confidence.